RT 234 inhalation - Respira Therapeutics

Drug Profile

RT 234 inhalation - Respira Therapeutics

Alternative Names: RT234 AOS™ DPI; RT234™

Latest Information Update: 18 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Respira Therapeutics
  • Developer Respira Therapeutics; United Therapeutics Corporation
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis; Pulmonary arterial hypertension; Pulmonary hypertension

Most Recent Events

  • 12 Apr 2017 Respira Therapeutics plans a phase I study in Pulmonary Arterial Hypertension (In volunteers) in Australia (ACTRN12618001077257p)
  • 12 Apr 2017 Preclinical trials in Idiopathic pulmonary fibrosis in USA (Inhalation)
  • 12 Apr 2017 Preclinical trials in Pulmonary arterial hypertension in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top